XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Unaudited Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock
Additional paid-in capital
Additional paid-in capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive income (loss)
Accumulated deficit
Accumulated deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2021     107,509,096          
Beginning balance at Dec. 31, 2021 $ 596,593 $ (22,147) $ 108 $ 1,018,005 $ (30,794) $ 6,083 $ (427,603) $ 8,647
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation expense 35,998     35,998        
Common stock issued under employee stock plans, net (in shares)     2,057,101          
Common stock issued under employee stock plans 6,111   $ 2 6,109        
Taxes paid related to net share settlement of equity awards (28,825)     (28,825)        
Unrealized loss on derivative instruments (3,179)         (3,179)    
Unrealized gain (loss) on available for sale securities (10)         (10)    
Net loss (48,763)           (48,763)  
Ending balance (in shares) at Mar. 31, 2022     109,566,197          
Ending balance at Mar. 31, 2022 535,778   $ 110 1,000,493   2,894 (467,719)  
Beginning balance (in shares) at Dec. 31, 2022     107,673,052          
Beginning balance at Dec. 31, 2022 502,125   $ 108 1,055,048   (9,557) (543,474)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Stock-based compensation expense 35,811     35,811        
Common stock issued under employee stock plans, net (in shares)     2,218,811          
Common stock issued under employee stock plans 5,853   $ 2 5,851        
Taxes paid related to net share settlement of equity awards (16,864)     (16,864)        
Repurchase of common stock (in shares)     (100,000)          
Repurchase of common stock (2,519)   $ 0 (2,519)        
Unrealized loss on derivative instruments (4,980)         (4,980)    
Unrealized gain (loss) on available for sale securities 156         156    
Net loss (38,304)           (38,304)  
Ending balance (in shares) at Mar. 31, 2023     109,791,863          
Ending balance at Mar. 31, 2023 $ 481,278   $ 110 $ 1,077,327   $ (14,381) $ (581,778)